Perrigo Company plc (PRGO) Earnings Call Transcript
November 4, 2026
Earnings Call Speaker Segments
Hello and welcome, everyone, whether you're joining us this morning or this afternoon, to Perrigo's conference call covering third quarter 2026 earnings. Today's release, together with the presentation that goes with it, is available for you in the Investors section of perrigo.com. Joining us are Albert Manzone, Perrigo's Interim President and CEO, and Eduardo Bezerra, our CFO. A quick reminder: we recently announced an agreement to divest our infant formula business. When we report fourth quarter and full year 2026 results, infant formula will be presented as discontinued operations. Because of that, the company's all-in outlook no longer includes infant formula. Our core outlook still excludes infant formula as well as the divestitures we previously announced. In this presentation, participants will make certain forward-looking statements. For details on those statements—which carry significant risks and uncertainties—please consult the slides. We'll be citing adjusted financial measures that are non-GAAP in nature. The appendix to the earnings presentation contains further information along with reconciliations of every non-GAAP measure presented to its GAAP counterpart. Turning to the agenda. Albert will open with his view of Perrigo and the priorities he has identified. After that, he'll cover how we performed in the third quarter, our progress on the Three-S plan, and the commercial opportunities he sees for driving growth that is stronger and more consistent. Eduardo will follow with a financial review and a discussion of our 2026 outlook. Albert, over to you.
Thanks, Eric. Good morning, good afternoon, and thank you for being with us on today's call. During the first five months I have been at Perrigo, I have devoted a considerable amount of time to listening to our customers, our consumers, and our people, digging into the business and our capabilities, and building a deeper understanding of what we do well and where we can be better. And I have grown increasingly impressed. We have leading store brand products, strong brands, attractive positions across our categories, and a talented organization that knows the consumer self-care business exceptionally well. I want to thank our teams across Perrigo for their hard work, commitment, and the way they have welcomed me. Meanwhile, we now understand clearly the reason those advantages haven't reliably shown up in the outcomes we ought to be achieving. Perrigo has grown overly complicated over the years. The company hasn't been brought together as fully as it should be, and that complication has made it more difficult for our people to act with the speed and focus required. We're taking firm steps to make Perrigo simpler and stronger, and for me that effort is a central priority. What that requires is a very disciplined approach to selecting our investment targets, to the markets and business lines we compete in, and to the way we structure the organization; our goal is for our skilled teams to concentrate on the spaces where Perrigo holds the strongest claim to succeed and where the risk-adjusted returns look most appealing to us. That effort is already in motion, and over the course of today's call you'll hear about how we are honing our focus, making the business simpler, and putting Perrigo in position to perform with greater consistency as time goes on. Turning to the main points from the quarter. To begin, our Three-S plan is delivering results. Plenty of work remains, yet operating performance came in better than the prior period, and we are gaining ground in the areas within our control. Divesting the infant formula business marks a significant move — it streamlines both our portfolio and our operations, lifts our margin profile, lowers expected future CapEx, and lets us direct our people and resources toward the areas where we hold the strongest right to win. On the competitive front, we picked up share once more in U.S. store brand OTC as well as across our key European brands. Category trends are likewise continuing to strengthen sequentially, though the consumer environment stays difficult in some areas. Lastly, we've revised our 2026 outlook to account for the infant formula divestment, a more cautious approach to retailer inventory positioning ahead of cough and cold season, and ongoing softness in Europe. Although trends in cough and cold occurrence are beginning to look somewhat better, retailers have responded by managing inventory more cautiously. Later in this call, Eduardo will walk you through the specifics, including the main factors behind what we expect for the rest of the year. Now a quick look at our third quarter financial results. As you can see, those results still mirror several ongoing difficulties we have already covered, among them how retailers are positioned on inventory and lower contract volumes. For me, the main point is simple. The areas of the business we can control are improving, even as external pressures continue to weigh on the figures we report. The sequential trends make this clearer to see. Our operating performance has strengthened in every quarter of this year. The year-over-year drop in core net sales has eased from 8.3% in Q1 to 3.1% in Q2 and then to 1.7% in Q3. Meanwhile, core adjusted operating margin has kept moving higher, rising from 12.8% to 13.4% to 14.3%; that represents real progress. Category trends are getting better, and what we are doing through the Three-S plan is making a difference. What we need to do now is build on that, keep simplifying Perrigo, and turn this progress into steadier results. Beyond the sequential gains in operating performance, the category environment is also improving. As you can see, consumption trends have picked up since the start of the year in both the U.S. and Europe; in the U.S., category volume came back to modest growth during the third quarter, while in Europe consumer trends are still soft, though the pace of decline kept getting better sequentially, and our execution is improving too. Now let me turn to the specifics of our recent progress. Under stabilize, operations are growing more consistent, service is getting better, and that is deepening our relationships and boosting collaboration with retail customers. With streamline, we're making deliberate decisions about where Perrigo ought to compete; Dermacosmetics has been sold, we've announced the divestment of infant formula, and the strategic review of oral care continues; we're also taking out cost. Savings of $42 million year-to-date have come from our Operational Enhancement Program, which remains on track to generate roughly $60 million-$80 million in 2026. With strengthen, we're putting additional investment behind innovation, demand generation, and the portfolio areas that present the biggest opportunity. The payoff is visible in our share performance in U.S. store brand OTC and across our key European brands. As we make Perrigo simpler, we can sharpen our focus on driving growth. In three areas, I see clear opportunities. The first is innovation. Our innovation investments are focused on categories where we hold a legitimate right to win and where differentiated products can deliver meaningful value to consumers and customers. Next, distribution. Store brand represents a core Perrigo strength, and we can place more of our products before more consumers. That includes e-commerce, where our market share already exceeds the total market. I will come back to that shortly. Third, demand generation. We are directing investment toward the brands, products, and customer programs where we believe attractive returns are achievable; that means stronger customer partnerships and more effective consumer engagement. The goal is straightforward: gain share and outgrow our categories. Let me illustrate some of those growth building blocks with a few examples. When it comes to store brands, we keep discovering fresh approaches to help shoppers and generate value for our retail partners. Our GLP-1 activation illustrates this well — we're placing our digestive health portfolio to assist consumers throughout their GLP-1 journey while strengthening our strategic ties with customers. Crucially, efforts such as this move a larger portion of our business into category segments that are expanding more quickly. Meanwhile, the money we put behind key brands is producing robust growth and share results. Compeed, Opill, ellaOne, and Jungle Formula each post growth and pick up share, showing what's possible when focused investment goes behind differentiated brands. These cases highlight the strengths of both sides of Perrigo. Our portfolio includes a distinctive set of store-brand products plus brands offering substantial growth potential. E-commerce, as I mentioned before, is an especially attractive avenue for Perrigo. This channel grows more quickly than the wider category, and our online share is larger than our share of the total market—which is significant. Since a growing portion of consumer buying is moving online, we should benefit to a greater extent; we are already seeing that happen. U.S. e-commerce volume for the total category has risen almost 15% year-to-date, and online sales now represent 22% of our U.S. volume, up from roughly 13% in 2022. We have a solid position in a channel that is expanding. Our job is to keep building on it. The strongest evidence that the Three-S plan is delivering shows up in our share results; in U.S. store brand OTC, volume grew 2% during the quarter, and we gained 30 basis points of share. For Europe, value sales of our key brands rose 6.5%, substantially outpacing their categories, and added 80 basis points of share; these are meaningful proof points; there is more opportunity ahead of us, yet wherever we invest and execute effectively, we succeed. Let me close by describing where my attention is focused. We have to capitalize on the share momentum we are seeing and continue broadening access to high-quality, affordable self-care products. We have to keep making Perrigo simpler. Divesting the infant formula business marks a significant move, though additional work is still required. Strengthening the balance sheet and building more financial flexibility are priorities for us. So that our capital allocation framework remains consistent with both our strategy and market opportunities, we regularly evaluate how best to deploy capital among growth investments, debt reduction, and returns to shareholders—and that includes reviewing the dividend every quarter. Execution is essential. There is still work to do, yet I am confident that our portfolio, our capabilities, and our people can get it done; with that, I'll turn things over to Eduardo, who will take you through the financial results in greater detail.
Thank you, Albert. I'm grateful to everyone for being here today. Unless otherwise noted, my remarks will center on adjusted non-GAAP results, with the exception of references to net sales. Moving to our Q3 results, beginning with the top line. Core net sales fell 1.7% versus the prior year, and core organic net sales were down 1.1%. As Albert emphasized, this is significant: it represents yet another quarter of sequential improvement, driven both by our ongoing execution of the Three-S plan and by category trends that are improving across several of our key markets. Third quarter results continued to mirror a consumption environment that remains softer. That softness—especially pronounced in our European business—drove retailers to position inventory more measuredly ahead of the cough and cold season in the self-care segment. Together, these factors created a headwind to growth of roughly 2 percentage points. Reduced contract manufacturing volumes added a further headwind of about 1 percentage point. On an encouraging note, our growth-building initiatives kept gaining traction, offsetting a meaningful share of those pressures. Innovation and market share gains delivered roughly 1.5 percentage points of growth in the quarter. Although the external environment stayed challenging, these actions strengthen our confidence in the business's underlying trajectory. In self-care, net sales dropped 3.2%. The decrease was concentrated in upper respiratory and pain and sleep categories, where softer consumption led retailers to position inventory more measuredly. Lower contract manufacturing volumes also pressured results. Partially offsetting these factors was growth in healthy lifestyle, backed by continued share gains in store brand nicotine replacement and in digestive health, where store brand laxative volumes rose. Specialty care net sales fell 4.6%. Women's health kept performing well, led by share gains and solid momentum in ellaOne, plus continued growth from Opill. In skin health, Compeed and Jungle Formula posted strong in-season performance, but that growth was more than offset by lower store brand and contract manufactured minoxidil sales and by lower Mederma sales. On an all-in basis, net sales came to $989 million, down 5.2%. Beyond the core drivers I just covered, all-in results also reflected divestitures and lower infant formula sales, which combined created a 3.2% headwind. Infant formula net sales fell 9.6%, as store brand formula growth was more than offset by lower contract volumes, including the timing of certain shipments recorded in the second quarter. Currency translation was a headwind of 0.5 percentage points. Now to adjusted operating income. Self-care adjusted operating income declined $25 million, or 19.4%. The drop was driven mainly by lower sales, particularly in our higher-margin European business, producing unfavorable mix along with higher advertising and promotional investment. Benefits from the Operational Enhancement Program partly offset those pressures. Specialty care adjusted operating income declined $10 million, or 24.2%, reflecting unfavorable mix in skin health and higher advertising and promotion investment across the segment; these investments continue to support the consumer programs and innovation activity Albert discussed, while Operational Enhancement Program savings provided a partial offset. Adjusted operating income for infant formula fell roughly $15 million and ended up slightly negative for the quarter. The drop in sales and gross profit flow-through, which included planned under absorption, was partly offset by reduced operating expenses. In all other, adjusted operating income rose about $4 million, or 18.4%. Those results got a boost from recognizing our recovery of a portion of tariffs paid previously, plus better productivity and lower operating expenses in oral care. Those gains more than offset the hit from divestitures. Corporate expenses showed modest year-over-year improvement, driven by ongoing cost discipline and benefits from the Operational Enhancement Program, partly offset by variable employee compensation returning to normal levels. Now on to margins. The drivers matched what I just laid out in the segment results. Core adjusted gross margin fell 140 basis points to 37.9%, pressured by lower net sales volumes and unfavorable mix stemming from reduced sales in our higher-margin European business, partly offset by the tariffs benefit and contributions from continued market share gains. Core adjusted operating margin dropped 210 basis points to 14.3%. Beyond the gross margin pressure, operating expenses rose mainly because of higher advertising promotion investment and variable employee compensation normalizing. That increase was partly offset by $19 million in Operational Enhancement Program benefits. All-in adjusted gross margin declined 370 basis points to 36.3%, reflecting the core drivers along with the impact of divestitures and a lower infant formula gross margin, including planned under absorption. All-in adjusted operating margin fell 360 basis points to 13.1%, reflecting those same items plus the impact of infant formula and divestitures. Third quarter core adjusted earnings per share came in at $0.61, down $0.06 from the prior year. Lower sales and operating income were partly offset by a lower adjusted effective tax rate. Shifts in the jurisdictional mix of earnings brought the adjusted effective tax rate down to 3.5% and benefited core adjusted earnings per share by roughly $0.10 in the quarter. The Q3 tax rate benefit included a year-to-date catch-up to reflect the updated jurisdictional mix of earnings. All-in adjusted diluted earnings per share was $0.60, down $0.20 from the prior year; beyond the core drivers, all-in earnings per share reflected the impact of divestitures and infant formula, including approximately $0.12 of unfavorable earnings per share impact from planned under absorption within infant formula. Moving to cash flow. Third quarter 2026 cash from operating activities was $96 million, in line with our expectations. Capital expenditures totaled $18 million, and we returned $40 million to shareholders through dividends. Now the balance sheet. Cash and cash equivalents were $437 million, and total debt was $3.3 billion. After quarter end, we announced an agreement to divest the infant formula business. Net proceeds are expected to be deployed in line with our capital allocation priorities, including sustainable business growth, reducing total debt and net leverage, and maintaining a disciplined and balanced capital allocation framework. Now turning to our outlook. As Eric said earlier, beginning from this point, we will report the infant formula business as discontinued operations. Turning first to core: reported net sales are now projected to fall 2.5%-3.6%, while organic net sales are expected to drop 2.7%-3.8%. Adjusted gross margin is forecast at 37.5%-38.5%, adjusted operating margin at 14%-15%, and adjusted diluted earnings per share between $2.15 and $2.35. On an all-in basis, which no longer includes infant formula but does include other divestitures, reported net sales are expected to decrease 4.6%-5.7%. Since infant formula now sits in discontinued operations, we anticipate a boost to adjusted gross margin and operating margins relative to the prior all-in outlook. Adjusted gross margin is now expected at 37.8%-38.8%, with adjusted operating margin of 14.3%-15.3%. All-in adjusted diluted earnings per share should land between $2.25 and $2.45. Under both core and all-in, our assumptions include net interest expense of roughly $162 million, an adjusted effective tax rate of about 14% for the year, and diluted shares outstanding of approximately 140 million. We likewise anticipate year-end net leverage near four times adjusted EBITDA. All-in cash from operating activities as a share of adjusted net income should come in around the low to mid-60% range. Two main factors drive the revision to our outlook: a more measured retailer inventory stance ahead of the cough and cold season, and ongoing weakness in the European consumer environment. Although cough and cold incidence has been trending favorably in the early part of the fourth quarter, after two straight seasons of softer category volumes retailers have adopted a more conservative approach to inventory. Consequently, third-quarter retailer inventory build came in below what we had previously assumed, which weighs on our sales outlook even though early illness trends and tracked channel consumption remain encouraging. In Europe, conditions for consumers stay difficult and are running under our earlier expectations. Given that, we consider it prudent to adopt a more measured view for the remainder of the year. Our operating assumptions keep incorporating gains from market share, innovation, distribution expansion, demand generation efforts, and productivity benefits tied to our Operational Enhancement Program. Entering the fourth quarter, our focus stays on turning market share gains and commercial investments into sales, controlling costs with discipline, and delivering against our updated outlook. Although we stay mindful of the uncertain consumer environment and the potential for variability in seasonal incident levels, we believe the steps we are taking put Perrigo in position to exit 2026 as a simpler, more focused consumer self-care company. Before handing the call to Eric, I want to thank every one of our colleagues across Perrigo for their continued focus, commitment, and diligent execution. Eric.
Thank you, Eduardo. Operator, we are now ready for questions.
Hello there, and good morning. I appreciate you taking the time for my questions, and congratulations on the infant formula divestiture. Now that the infant formula has been sold, I suppose taking a step back, how are you viewing the company's strategy? Has anything shifted on that front? Is oral care still intended to be divested, and what's the status of that business? Are there additional parts of the business that you believe would be sensible to divest? And then, any news on your approach for the store brands and the branded portion of the business? Thank you.
Good morning, Susan, and thanks for asking. I hope you're doing well. Listen, as you mentioned, we are pleased with the infant formula sale. On oral care, that process continues, and right now those are the two assets we're examining as a whole. What that means for us, as I mentioned in my earlier remarks, is really the ability to focus, simplify the company, and really concentrate on driving growth, improving our margins, and allocating capital in a disciplined way. From a strategic standpoint, I think this is a big opportunity that we have. I believe over the quarters ahead, you'll see more of that. We're very pleased with the market share gains we're demonstrating and the progress we're showing in the areas we control for this quarter. We keep looking at continuing to do better as we move forward. Strategically, there are areas that I think are very promising when you look at our sales performance, innovation, and focusing innovation where we get the best value for our brands, capturing the e-commerce opportunities. As you saw in the presentation, we hold a higher market share in a category that is growing and already accounts for 20% of our sales in the U.S. I think we're going to double down on that focus with the organization going forward.
All right, great. So maybe I could just follow up on the market share gains during the quarter. I suppose you could go into more detail about which categories you're picking up share in, both for store brands and then separately for your branded business. I guess, are the gains happening throughout the whole portfolio, or are there particular categories or brands where the biggest market share gains are coming through? Thanks.
Yes, good question. Looking at the U.S., things are going well for us in the majority of categories. As you know, we're placing a great deal of emphasis on rebuilding the business alongside the retailer. I spoke with you last quarter, and this forms part of sequential improvements in terms of bettering our service levels to those retailers, and with our key retailers who are 95% and above. We keep working at that. That enables us, as I mentioned earlier last quarter, to sit down with those retailers and co-innovate alongside them, and also to create demand generation; we do have a number of tests underway when it comes to generating demand for the store brands. That growth holds steady across the board, somewhat less in oral electrolytes and skin health, largely because of one brand there, minoxidil. Across all the others, you're seeing progress. You're also seeing fresh opportunities, as, for instance, we're bundling digestive health together for GLP-1 consumers, and we're rolling this out with a number of retailers right now. You know that we're picking up share within the store brands, but we also see opportunities to gain share as the total store brand business on behalf of the retailers; this is something they're keen to develop. This is something that I believe the consumer is watching. As I told you earlier, when you look at e-commerce and when you look at the agents, it's easy to picture that an AI agent will at some point recommend a brand costing far less that contains exactly the same FDA ingredients; those are opportunities we're carrying forward that let us gain share. What you see in Europe is share gains too across all our significant, I'd say, bigger brands. There, we're performing well. We need to ensure we support more broadly some of the other brands, and in Europe we sometimes have a leaky bucket. This is an area I'm focused on, going into some of those brands that have potential with a bit of support. Those market share trends and our overall position in Europe can keep growing as we move forward.
All right, excellent. Appreciate the thorough rundown. Best of luck for the remainder of the year.
Thanks a lot.
Hi, Ethan here, filling in for Chris Schott. Thanks for taking our questions, and congratulations on the quarter. To start off, as we look ahead perhaps to 2027 and given how many moving pieces there are in the business, how are you thinking about the main pushes and pulls? Along those lines, could you quantify the benefit from the tariff reversal this quarter?
Yes. Good morning, Ethan. As you might expect, I'll be saying less about 2027, and you'll hear more on that next quarter. Let me perhaps walk you through some of the positives as I see 2027, along with some of the watch-outs. On the positive side, I think you're going to see an improvement in the under absorption on OTC, which, as you remember, was negatively impacted in the first half of 2026. You're going to keep seeing Operational Enhancement Programs, which we're working on and feel comfortable about. We're continuing — you're going to see margin improvement from the divestment of infant formula in 2027. The watch-out, and this shouldn't surprise you, is that obviously the Dermacosmetics divestiture has taken place. You'll see a normalization of the tax rate, which, as you know, has been positive this year due to the jurisdictions where it took place. The one-time benefits on the tariffs are going to go away. We continue to see, of course, inflationary pressure, and those will still be coming in 2027. Along with that, we're going to make sure, as I said in my opening statement, that we invest where it does matter behind our brands, behind innovation, demand generation. The key for us is going to grow the business next year, and that's what we intend to do.
Ethan, on your tariff question, for Q3 the tariff benefit came to roughly $4.5 million. Alright?
Great. That's really useful. Another thing I'd ask is just, after the impact or after the infant formula divestiture, how are you viewing the company's cash flow more broadly going forward, and perhaps especially, how big an effect on CapEx will this divestiture have? Thank you.
Yeah, Ethan. Eduardo, do you want to handle this one?
Yes. Ethan, I believe there are a few points to address there. To start, as we said when we established guidance for this year, infant formula was using up cash due to how this year performed. With this divestment, I believe we eliminate that uncertainty. In addition, as you’ll recall, we noted a couple of years back that we would invest substantially to optimize our entire network and footprint. At that point, we disclosed a potential $240 million. We carried out a small share of those investments during the last two years to ensure we kept operations running and completed some previously committed investments; going forward, this will mean a substantial decrease in our capital requirements. The upside there is that we’ll be able to redirect our focus toward our core. OTC business, correct? Since we see opportunities to invest in various areas that we believe will deliver better potential returns and align more closely with our ongoing core strategy.
Excellent. Many thanks, everyone, for those questions, and congratulations once more on the quarter.
Thanks, Ethan.
Hello, this is Machado Rodriguez filling in for Daniel. Appreciate you taking my question. You mentioned that inventory positioning has been more cautious going into cough and cold season. To be clear, are retailers cutting stock levels again on purpose, or is it simply that they aren't restocking before the season?
Yes, thanks for asking. That's a good question. What I'd say is that during Q3, we didn't observe retailers doing what you described in the second part of your assumption. They didn't load up for the season the way they could have, or the way they did previously. The season's start appears to be pushing later into the year, given climate change and so forth. That's what you've been seeing. So from our standpoint, we keep seeing a season that ought to be stronger than last year, though perhaps not as strong as first estimated. Having said that, I believe it's too soon to say, because as we speak, temperatures are dropping and more people are falling ill. We observed some encouraging signs in October out of the Southwest of the U.S.; in Europe, cough and cold season is beginning to arrive. We're prepared for replenishments, no problems there. The real question is whether it will affect Q4. Will it affect Q1? Again, this season appears to be moving on the calendar.
All right, great, thanks. Just a quick follow-up on that: do you think restocking could act as a tailwind for sales, or are retailers likely to keep inventory levels lower from here on?
My view is that if the season gains momentum — and that's still up in the air — replenishment will come. What I can't tell you again is whether that replenishment lands more in Q4 or in Q1 of next year.
All right, fantastic. I appreciate the questions and congratulations on the quarter.
Thanks.
Thank you, Anas, and thank you all for joining and for your questions.
Let me wrap up with something—no, wait, if you'll permit me, I simply want to add a few thoughts, because I wanted to share some observations about what I've observed at this company across the last five months. Perrigo occupies a position that is difficult to replicate; in U.S. store brands OTC, we hold the leading spot. In Europe, we possess a portfolio of leading brands. Hardly any companies are able to serve consumers across brands, store brands, categories, and price points in the manner that we do. That affords us the capacity to capture demand as consumer preferences shift. We are picking up share on both sides of the Atlantic, and e-commerce is producing additional gains. Our e-commerce share already exceeds our share of the total market, and as more purchasing migrates online, we ought to benefit to a larger degree. What has restrained this company is not the assets—it is complexity. That is precisely what we are removing quarter by quarter. Real work lies ahead to simplify Perrigo, to execute with greater consistency, and to optimize our capabilities and assets so as to drive stronger performance; we know what we have to do, we are doing it, and I am confident in where we are headed. Thank you all for your continued interest in Perrigo.
Thank you, everyone — that brings today's conference call to a close. We appreciate your joining us, and we'd ask you to go ahead and disconnect your lines now. Have a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Perrigo Company plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Perrigo Company plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.